SELLAS Life Sciences Group Inc (SLS)
1.26
+0.02
(+1.61%)
USD |
NASDAQ |
Oct 04, 16:00
1.26
0.00 (0.00%)
After-Hours: 20:00
SELLAS Life Sciences Group SG&A Expense (Annual): 13.86M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 13.86M |
| December 31, 2022 | 12.58M |
| December 31, 2021 | 11.32M |
| December 31, 2020 | 9.60M |
| December 31, 2019 | 9.923M |
| December 31, 2018 | 12.77M |
| December 31, 2017 | 15.09M |
| December 31, 2016 | 4.593M |
| December 31, 2015 | 10.61M |
| Date | Value |
|---|---|
| December 31, 2014 | 16.23M |
| December 31, 2013 | 8.065M |
| December 31, 2012 | 6.585M |
| December 31, 2011 | 8.635M |
| December 31, 2010 | 8.752M |
| December 31, 2009 | 8.628M |
| December 31, 2008 | 7.499M |
| December 31, 2007 | 4.691M |
| December 31, 2006 | 0.633M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
9.60M
Minimum
2020
13.86M
Maximum
2023
11.46M
Average
11.32M
Median
2021
SG&A Expense (Annual) Benchmarks
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 12.27M |
| iBio Inc | 11.67M |
| Theriva Biologics Inc | 7.12M |
| Oragenics Inc | 5.452M |